Acronym
AcTakines
Code
3G009614
Duration
01 January 2014 → 31 December 2019
Funding
Research Foundation - Flanders (FWO)
Promotor
Research disciplines
-
Natural sciences
- Biochemistry and metabolism
- Systems biology
-
Medical and health sciences
- Medical biochemistry and metabolism
- Morphological sciences
- Oncology
- Medical biochemistry and metabolism
- Morphological sciences
- Oncology
- Medical biochemistry and metabolism
- Morphological sciences
- Oncology
Keywords
receptor
cancer
cytokines
Project description
Systemic toxicity prevents full clinical application of cytokines such as type I interferons or Tumor Necrosis Factor, including their use in cancer. We will evaluate a novel strategy to selectively target cytokine activity in vivo, aiming at an up to 1000-fold enhanced activity on cells expressing a specific surface marker. We will develop so-called AcTakines (Activity-on-Target cytokines), which resemble immunocytokines but employ mutant cytokines with reduced binding affinity for their receptor complex.